浏览全部资源
扫码关注微信
贵州中医药大学,贵阳 550025
罗运凤,在读硕士,从事中医证候物质基础研究,E-mail:704973070@qq.com
蒋志滨,博士,副教授,从事方剂配伍规律与作用机制研究,E-mail:624184837@qq.com
纸质出版日期:2021-01-20,
网络出版日期:2020-08-31,
收稿日期:2020-05-31,
扫 描 看 全 文
罗运凤,高洁,柴艺汇等.痛泻要方对肝郁脾虚型溃疡性结肠炎模型大鼠结肠SERT,肝脏5-HT2AR蛋白表达的影响[J].中国实验方剂学杂志,2021,27(02):15-21.
LUO Yun-feng,GAO Jie,CHAI Yi-hui,et al.Effect of Tongxie Yaofang on Expressions of Colon SERT and Liver 5-HT2AR Proteins in Rats with Ulcerative Colitis Model of Liver Stagnation and Spleen Deficiency[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(02):15-21.
罗运凤,高洁,柴艺汇等.痛泻要方对肝郁脾虚型溃疡性结肠炎模型大鼠结肠SERT,肝脏5-HT2AR蛋白表达的影响[J].中国实验方剂学杂志,2021,27(02):15-21. DOI: 10.13422/j.cnki.syfjx.20202103.
LUO Yun-feng,GAO Jie,CHAI Yi-hui,et al.Effect of Tongxie Yaofang on Expressions of Colon SERT and Liver 5-HT2AR Proteins in Rats with Ulcerative Colitis Model of Liver Stagnation and Spleen Deficiency[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(02):15-21. DOI: 10.13422/j.cnki.syfjx.20202103.
目的
2
观察痛泻要方对肝郁脾虚型溃疡性结肠炎(UC)模型大鼠结肠5-羟色胺转运体(SERT),肝脏5-羟色胺(5-HT)
2A
受体(5-HT
2A
R)蛋白及血清5-HT,炎症因子等表达的影响,探讨肝郁脾虚证候基础及痛泻要方干预机制。
方法
2
将50只SD雄性大鼠随机分为正常组,模型组,痛泻要方高、中、低剂量组(10,5,2.5 g·kg
-1
),柳氮磺嘧啶组(0.3 g·kg
-1
)。采用2,4,6-三硝基苯磺酸(TNBS)/乙醇溶液灌肠+束缚应激+饮食失节建立肝郁脾虚型溃疡性结肠炎模型。造模成功后,给予相应药物干预21 d后取材,采用苏木素-伊红(HE)染色,油红O染色分别观察各组大鼠结肠、肝脏病理学改变。酶联免疫吸附测定(ELISA)检测大鼠血清白细胞介素(IL)-6,IL-9,5-HT,超氧化物歧化酶(SOD)水平,蛋白免疫印迹法(Western blot)检测大鼠结肠SERT,肝脏5-HT
2A
R蛋白表达。
结果
2
与正常组比较,模型组结肠形成明显溃疡,肝脏脂滴形成增加。血清IL-6,IL-9,5-HT水平上升,SOD水平明显下降(
P
<
0.05),结肠SERT蛋白表达量显著下降,肝脏5-HT
2A
R蛋白表达量明显上升(
P
<
0.05);与模型组比较,痛泻要方高、中剂量组及柳氮磺嘧啶组结肠病理损伤得到改善,肝脏脂滴形成减少。痛泻要方各剂量组及柳氮磺嘧啶组血清IL-6,IL-9,5-HT水平均下降,SOD水平明显上升(
P
<
0.05)。痛泻要方高、低剂量组及柳氮磺嘧啶组结肠SERT蛋白表达量上升,痛泻要方中、低剂量组及柳氮磺嘧啶组肝脏5-HT
2A
R蛋白表达量明显下降(
P
<
0.05)。
结论
2
痛泻要方可能通过上调结肠SERT的表达,从而降低5-HT的含量,调节肠道动力及感觉系统;抑制IL-6,IL-9等炎性因子的表达,发挥抗炎作用;降低5-HT含量及肝脏5-HT
2A
R表达,升高SOD水平,调节情志及肝脏脂质代谢,发挥对肝郁脾虚型溃疡性结肠炎干预作用。
Objective
2
To observe the effect of Tongxie Yaofang on the expressions of colon serotonin transporter (SERT), liver 5-hydroxytryptamine
2A
receptor (5-HT
2A
R) protein, serum 5-HT and inflammatory factors in ulcerative colitis (UC) model rats of liver stagnation and spleen deficiency, in order to explore the basis of syndrome of liver stagnation and spleen deficiency and the intervention mechanism of Tongxie Yaofang.
Method
2
Fifty male SD rats were randomly divided into blank control group, model group, high, medium and low-dose Tongxie Yaofang group (10,5,2.5 g·kg
-1
), and salazosulacil group (0.3 g·kg
-1
). The ulcerative colitis model of liver depression and spleen deficiency was established by 2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol solution enema + restraint stress + diet loss. After successful modeling, the samples were collected after 21 days of drug intervention. Htoxylin eosin (HE) staining and oil red staining were used to observe the pathological changes of colon and liver in each group. Serum interleukin-6 (IL-6), IL-9, 5-HT and superoxide dismutase (SOD) were detected by enzyme linked immunosorbent assay (ELISA). Protein expressions of SERT in the colons and 5-HT
2A
R in liver of rats were detected by Western blot.
Result
2
Compared with the normal group, obvious ulcers were formed in the colon and lipid droplets in the liver increased in the model group, serum levels of IL-6, IL-9 and 5-HT in the model group increased, while the level of SOD decreased (
P
<
0.05). The protein expression of SERT in colon decreased, whereas the protein expression of 5-HT
2A
R in liver increased (
P
<
0.05). Compare with model group, the pathological damage of colon was improved, and the formation of lipid droplets in liver was reduced in high, medium-dose Tongxie Yaofang groups and sulfasalazine group. The serum levels of IL-6, IL-9 and 5-HT decreased, while the level of SOD increased in Tongxie Yaofang group and sulfasalazine group (
P
<
0.05). The protein expression of SERT in colon increased in high,low-dose Tongxie Yaofang groups and sulfasalazine group, and the protein expression of 5-HT
2A
R in liver decreased in medium, low dose Tongxie Yaofang groups and sulfasalazine group (
P
<
0.05).
Conclusion
2
Tongxie Yaofang may reduce the content of 5-HT, and regulate the intestinal motility and sensory system by up-regulating the expression of SERT in the colon, inhibit the expressions of IL-6,IL-9 and other inflammatory factors, and play an anti-inflammatory role, reduce the content of 5-HT and the expression of 5-HT
2A
R in the liver, increase the level of SOD, regulate emotion and lipid metabolism in the liver, and then exert the intervention effect on ulcerative colitis with liver depression and spleen deficiency on the whole.
痛泻要方溃疡性结肠炎白细胞介素-6(IL-6)IL-95-羟色胺(5-HT)5-羟色胺转运体(SERT)5-HT2A受体(5-HT2AR)
Tongxie Yaofangulcerative colitisinterleukin-6 (IL-6)IL-95-hydroxytryptamine (5-HT)serotonin transporter (SERT)5-HT2A receptor(5-HT2AR)
KHOR B,GARDET A,XAVIER R J.Genetics and pathogenesis of inflammatory bowel disease[J].Nature,2011,474(7351):307-317.
王移飞,王凤仪,徐兰萍,等.芍药汤经HMGB1调节湿热型溃疡性结肠炎大鼠MyD88和NF-κB的分子机制[J].中国实验方剂学杂志,2018,24(12):86-91.
SILVA BRUNO CESAR D A,CASTRO L A,RAQUEL R,et al.Epidemiology,demographic characteristics and prognostic predictors of ulcerative colitis[J].World J Gastroenterol,2014,20(28):9458-9467.
TADA Y,ISHIHARA S,KAWASHIMA K,et al.Down-regulation of serotonin reuptake transporter gene expression in healing colonic mucosa in presence of remaining low grade inflammation in ulcerative colitis[J].J Gastroenterol Hepatol,2015,31(8):1443-1452.
甄建华,黄光瑞.溃疡性结肠炎病因和发病机制的现代医学研究进展[J].世界华人消化杂志,2019,27(4):245-251.
张声生,沈洪,郑凯,等.溃疡性结肠炎中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(8):3585-3589.
崔国宁,刘喜平.痛泻要方治疗溃疡性结肠炎研究进展[J].辽宁中医杂志,2018,45(5):1113-1116.
林燕,李兴广.基于肠易激综合征的脑-肠互动与肝郁脾虚实质探讨[J].世界中医药,2009,4(6):304-306.
厉启芳,刘善军,景德怀,等.基于临床疗效及Th1/Th2、Th17/Treg炎性平衡变化探讨痛泻要方治疗溃疡性结肠炎的机制[J].辽宁中医杂志,2018,45(8):1569-1572.
孙羽中,陈富丽,窦志芳.痛泻要方对IBS肝郁脾虚证大鼠血清、结肠5-羟色胺的影响[J].山西中医学院学报,2017,18(6):20-23.
旺建伟,叶虹玉,赵文静,等.痛泻要方对IBS内脏高敏性大鼠结肠组织5-HT4受体mRNA与c-fos mRNA表达的影响[J].中华中医药杂志,2014,29(4):1070-1075.
BINIENDA A,STORR M,FICHNA J,et al.Efficacy and safety of serotonin receptor ligands in the treatment of irritable bowel syndrome:a review[J].Curr Drug Targets,2018,19(15):1774-1781.
GREEN WOOD-VAN MEERVELD B,MOHAMMADI E,TYLER K,et al.Synergistic effect of 5-hydroxytryptamine 3 and neurokinin 1 receptor antagonism in rodent models of somatic and visceral pain[J].J Pharmacol Exp Ther,2014,351(1):146-152.
陈富丽,窦志芳.两种肝郁脾虚型肠易激综合征动物模型的比较[J].山西中医学院学报,2014,15(3):73-74.
时军,李昕,张小灵,等.痛泻要方加减防风对实验性UC大鼠结肠黏膜的影响[J].中国实验方剂学杂志,2015,21(4):161-165.
刘佳,许可,张兰.肝郁脾虚证动物模型评价方法[J].中医药导报,2019,25(23):120-122.
罗丹妮,李瑛,周思远.高架十字迷宫在焦虑大鼠模型判定中的应用[J].福建医科大学学报,2019,53(2):132-136.
胡柳,卓泽伟,阮璐薇,等.肝郁证模型及其方法评价进展评述[J].中华中医药杂志,2019,34(1):41-43.
吴东升,曹晖,张彧,等.芍药汤对溃疡性结肠炎大鼠肠黏膜免疫屏障的干预作用[J].中国实验方剂学杂志,2019,25(9):6-11.
甄建华,黄光瑞.溃疡性结肠炎病因和发病机制的现代医学研究进展[J].世界华人消化杂志,2019,27(4):245-251.
赵昌东,赵红艳,柯希权,等.焦虑、抑郁心理与溃疡性结肠炎患者神经内分泌免疫的相关性研究[J].胃肠病学和肝病学杂志,2019,28(7):791-795.
田志颖,冯丽英,王丽华.5-羟色胺与焦虑、抑郁的关系及其在溃疡性结肠炎发病中的作用[J].胃肠病学和肝病学杂志,2011,20(9):827-828.
YANG Y,ZHU X W,QIN Y F,et al.The anti-inflammatory effect of guchangzhixie-pill by reducing colonic EC cell hyperplasia and serotonin availability in an ulcerative colitis rat model[J].Evid Based Complement Alternat Med,2017,doi:10.1155/2017/8547257http://dx.doi.org/10.1155/2017/8547257.
WANG Z L,WANG Y D,WANG K,et al.KFL2 participates in the development of ulcerative colitis through inhibiting inflammation via regulating cytokines[J].Eur Rev Med Pharmacol Sci,2018,22(15):4941-4948.
王倩,别玉龙,王豆,等.蒲公英多糖对溃疡性结肠炎大鼠IL-6/STAT3信号通路的影响[J].中国应用生理学杂志,2017,33(5):422-425.
TIAN L L,LI Y,ZHANG J,et al.IL-9 promotes the pathogenesis of ulcerative colitis through STAT3/SOCS3 signaling[J].Biosci Rep,2018,doi:10.1042/BSR20181521http://dx.doi.org/10.1042/BSR20181521.
宋囡,贾连群,杨关林,等.脾虚高脂血症大鼠肝脏miRNA-122a的表达及其与SREBP-2通路调控的关系[J].中华中医药杂志,2016,31(3):975-979.
COSTEDIO M M,HYMAN N,MAWE G M.Serotonin and its role in colonic function and in gastrointestinal disorders[J].Dis Colon Rectum,2007,50(3):376-388.
王珊珊,傅继华.外周5-羟色胺系统与肝脂代谢相关性的研究进展[J].北方药学,2014,11(7):62-63.
FU J,MA S,LI X,et al.Long-term stress with hyperglucocorticoidemia-induced hepatic steatosis with VLDL overproduction is dependent on both 5-HT2 receptor and 5-HT synthesis in liver[J].Int J Biol Sci,2016,12(2):219-234.
郭可可,傅继华.肝脏中五羟色氨及其受体与肝糖、脂代谢相关性的初步机制研究[J].临床合理用药杂志,2015,8(26):176-177.
YANG Y,AN S,LIU Y,et al.Novel serotonin receptor 2(5-HT2R)agonists and antagonists:a patent review(2004-2014)[J].Expert Opin Ther Pat,2016,26(1):89-106.
0
浏览量
12
下载量
5
CSCD
关联资源
相关文章
相关作者
相关机构